Armata Pharmaceuticals 2025 Annual Report: Key Financial and Strategic Highlights for Investors

Summary of Key Investor Highlights

• New \$100 Million “Capital on Demand” ATM Sales Agreement: In December 2025, Armata Pharmaceuticals entered into a Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC, allowing the company to offer and sell up to \$100 million of its common stock from time to time, subject to certain conditions. This provides significant potential liquidity for future operations and strategic initiatives, and the issuance of additional shares could impact existing shareholders through dilution.
• Convertible Loan Facility: The company has an \$8.0 million Convertible Loan due June 2027, bearing interest at 8% per annum. The loan is secured by substantially all of Armata’s and its subsidiaries’ assets. Notably, if Armata secures a Qualified Financing of at least \$30 million from new investors, the outstanding loan plus accrued interest will convert into common stock at a 15% discount to the lowest price paid in the new financing. Otherwise, the lender has the option to convert at the greater of book or market value (\$1.52/share as of the agreement date), subject to adjustment for corporate actions. This structure could lead to significant dilution in the event of conversion, especially if the company undertakes a large financing at a low share price.
• Public Float and Share Count: As of June 30, 2025, the aggregate market value of voting stock held by non-affiliates was approximately \$21.1 million. As of March 18, 2026, there were 36,632,775 shares of common stock outstanding. This share count is important for assessing potential dilution from the ATM or convertible loan conversions.
• SEC Reporting Status: Armata Pharmaceuticals is a smaller reporting company and a non-accelerated filer as of the report date. The company is not an emerging growth company and is not a shell company.
• Forward-Looking Statements: The company’s report contains numerous forward-looking statements regarding expected operating losses, capital requirements, potential financings, regulatory submissions, product development timelines, and the effects of government awards (notably a \$26.2 million DoD award). These are subject to risks including regulatory decisions, financing availability, competitive actions, supply chain and manufacturing capabilities, and global economic and geopolitical events.
• Potential Price-Sensitive Risks and Opportunities:
  • Potential for substantial dilution depending on the pace and terms of future equity offerings (ATM or loan conversion).
  • Ability to raise additional funds is critical to future operations and is explicitly highlighted as a material risk.
  • Ongoing investments in infrastructure, future growth expectations, patent protection, and exposure to macroeconomic/regulatory changes (e.g., conflicts in Ukraine/Middle East, bank failures) could affect financial performance and share value.
  • Company’s ability to maintain compliance with Sarbanes-Oxley internal controls and other regulatory requirements is noted as a key factor for investors.
• Document Incorporation: The company intends to incorporate its 2026 Proxy Statement by reference into Part III of the Form 10-K, meaning some information may be presented in a future filing.

Detailed Discussion for Investors

Liquidity and Fundraising

Armata’s new at-the-market (ATM) equity program with JonesTrading gives the company the ability to raise up to \$100 million in common stock over time. This is a substantial facility compared to its current public float and market cap, and any large or frequent issuance under this program could significantly increase the share count and dilute existing shareholders. Investors should closely monitor ATM activity, as well as the company’s cash burn and capital requirements disclosed in the management discussion.

Convertible Loan and Dilution Risk

The \$8 million Convertible Loan is a double-edged sword: while it provides needed capital and is secured against company assets, it also contains provisions that could trigger substantial share issuance in the event of a large financing round or at the lender’s option. The conversion price mechanics (15% discount to new financing, or greater of book/market value) mean that if the stock price is low at the time of conversion, dilution could be highly significant. Additionally, the company is required to keep registration statements effective for the potential resale of these shares, which could add selling pressure.

Pipeline and Government Awards

The company’s development pipeline remains focused on phage-based product candidates, with notable external support including a \$26.2 million Department of Defense (DoD) award, which is expected to fund specific research and development activities. The company’s ability to progress its programs is highly dependent on this and other non-dilutive funding, but the report also cautions that continued investment will likely be necessary, reinforcing the relevance of the ATM and loan facilities.

Regulatory, Geopolitical, and Macro Risks

Armata highlights a broad array of external risks, from FDA and global regulatory decisions to supply chain and competitive threats, as well as macroeconomic and geopolitical uncertainties (including ongoing wars and financial sector instability). These could have both positive and negative impacts on operational progress and share value.

Shareholder Considerations

• Investors should be aware of the possibility of increased share issuance, either through the ATM or through conversion of the convertible loan, both of which may be price sensitive and could cause downward pressure on the stock.
• The company’s ability to continue as a going concern is linked to successful fundraising and cost management.
• Regulatory compliance, management execution, and macroeconomic events are all highlighted as potentially material factors for future performance.

Conclusion

For investors, the 2025 Annual Report from Armata Pharmaceuticals contains several key items that could move the share price:

• The new \$100 million ATM sales agreement is a major capital-raising tool, but could lead to significant dilution if used aggressively.
• The \$8 million convertible loan could also result in material dilution if converted, especially if at a discounted price.
• Government awards and the company’s R&D progress remain critical, but future funding needs and the ability to execute on planned growth are also central risks and opportunities.
• Shareholders should monitor ATM activity, public filings, and future proxy statements for more details on executive compensation, corporate governance, and further risk disclosures.

Price-sensitive takeaway: The company’s expanded ability to issue shares both via the ATM and convertible loan conversion represents both a liquidity opportunity and a dilution risk. Investors should closely track future disclosures for updates on capital raising, regulatory progress, and pipeline milestones.

Disclaimer: This article is for informational purposes only and is not investment advice. All investments carry risk, and investors should conduct their own due diligence and consult with a financial advisor before making investment decisions. The information provided herein is based on the company’s 2025 Annual Report and may be subject to change or update in future filings.

View Armata Pharmaceuticals, Inc. Historical chart here